





LYVE1 Polyclonal Antibody, DyLight™ 488

Catalog Number PA5-22787 Product data sheet

Details	
Size	100 µL
Host/Isotope	Rabbit / IgG
Class	Polyclonal
Туре	Antibody
Immunogen	A synthetic peptide made to a C-terminal portion of the human LYVE-1 protein sequence (between residues 250-322).
Conjugate	DyLight™ 488
Form	Liquid
Concentration	0.69 mg/mL
Purification	Antigen affinity chromatography
Storage buffer	50mM sodium borate
Contains	0.05% sodium azide
Storage Conditions	4° C, store in dark

Species Reactivity		
Species reactivity	Human, Mouse	
Tested Applications	Dilution *	
Tested Applications Western Blot (WB)	Dilution * 2 μg/mL	

^{*} Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.

Product specific information

Suggested positive control: mouse spleen lysate.

Background/Target Information

LYVE1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module, the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves. LYVE1 is a type I integral membrane glycoprotein. LYVE-1 is expressed primarily on lymphatic vessel endothelium and is likely to be involved in regulating the traffic of leucocytes and tumor cells to lymph nodes. The lymphatic vasculature forms a second circulatory system that drains extracellular fluid from the tissues and provides an exclusive environment in which immune cells can encounter and respond to foreign antigen. A number of molecules have been identified as markers for lymphatic endothelium which include LYVE1, PALE, VEGFR3, and podoplanin. Diseases associated with LYVE1 dysfunction includes Complete Androgen Insensitivity Syndrome.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample

NO OTHER WARRANTIES, EXPRESS OR IMPLED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT, BUYER'S EXCLUSINE REALED FOR ROCKETOR POR REFUNDED FOR ROPE OF REFUNDED FOR PROBLEMENT, BUYER'S EXCLUSIVE REALED FOR ROCKETOR FOR REFUNDED FOR ROPE OF REFUNDED FOR ROPE

